Sebastian Kufner

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6267478/publications.pdf Version: 2024-02-01



1.2

19

#	Article	IF	CITATIONS
1	Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes. New England Journal of Medicine, 2019, 381, 1524-1534.	27.0	543
2	Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Trial. European Heart Journal, 2009, 30, 2441-2449.	2.2	207
3	Randomized Trial of Paclitaxel- Versus Sirolimus-Eluting Stents for Treatment of Coronary Restenosis in Sirolimus-Eluting Stents. Journal of the American College of Cardiology, 2010, 55, 2710-2716.	2.8	192
4	Neointimal Modification With Scoring Balloon and Efficacy of Drug-Coated Balloon Therapy in Patients With Restenosis in Drug-Eluting Coronary Stents. JACC: Cardiovascular Interventions, 2017, 10, 1332-1340.	2.9	98
5	Ten-Year Clinical Outcomes From a Trial of Three Limus-Eluting Stents With Different Polymer Coatings in Patients With Coronary Artery Disease. Circulation, 2019, 139, 325-333.	1.6	97
6	High-Sensitivity Troponin T and Mortality After Elective Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2016, 68, 2259-2268.	2.8	88
7	Long-Term Efficacy and Safety of Paclitaxel-Eluting Balloon for the Treatment of Drug-Eluting Stent Restenosis. JACC: Cardiovascular Interventions, 2015, 8, 877-884.	2.9	85
8	Five-year outcomes from a trial of three limus-eluting stents with different polymer coatings in patients with coronary artery disease: final results from the ISAR-TEST 4 randomised trial. EuroIntervention, 2016, 11, 1372-137.	3.2	60
9	Randomized Trial of Polymer-Free Sirolimus- and Probucol-Eluting StentsÂVersus Durable Polymer Zotarolimus-Eluting Stents. JACC: Cardiovascular Interventions, 2016, 9, 784-792.	2.9	52
10	10-Year Outcomes From a Randomized Trial of Polymer-Free Versus Durable Polymer Drug-Eluting Coronary Stents. Journal of the American College of Cardiology, 2020, 76, 146-158.	2.8	49
11	Long-term outcome after sirolimus-eluting stents versus bare metal stents in patients with Diabetes mellitus: a patient-level meta-analysis of randomized trials. Clinical Research in Cardiology, 2011, 100, 561-570.	3.3	38
12	ISARâ€₽EBIS (Paclitaxel‣luting Balloon Versus Conventional Balloon Angioplasty for In‧tent Restenosis) Tj E	TQq000	rg <u>BT</u> /Overlo
13	Prognostic Impact of Periprocedural Myocardial Infarction in Patients Undergoing Elective Percutaneous Coronary Interventions. Circulation: Cardiovascular Interventions, 2018, 11, e006752.	3.9	32
14	Covered stents for endovascular repair of iatrogenic injuries of iliac and femoral arteries. Cardiovascular Revascularization Medicine, 2015, 16, 156-162.	0.8	26
15	A meta-analysis of specifically designed randomized trials of sirolimus-eluting versus paclitaxel-eluting stents in diabetic patients with coronary artery disease. American Heart Journal, 2011, 162, 740-747.	2.7	24
16	Outcome after new generation singleâ€layer polytetrafluoroethyleneâ€covered stent implantation for the treatment of coronary artery perforation. Catheterization and Cardiovascular Interventions, 2019, 93, 912-920.	1.7	22
17	Long-Term Risk of Adverse Outcomes and New Malignancies in Patients Treated With Oral Sirolimus for Prevention of Restenosis. JACC: Cardiovascular Interventions, 2009, 2, 1142-1148.	2.9	20

ST-segment resolution after primary percutaneous coronary intervention in patients with acute
ST-segment elevation myocardial infarction. Cardiology Journal, 2012, 19, 61-69.

#	Article	IF	CITATIONS
19	Three-year efficacy and safety of new- versus early-generation drug-eluting stents for unprotected left main coronary artery disease insights from the ISAR-LEFT MAIN and ISAR-LEFT MAIN 2 trials. Clinical Research in Cardiology, 2016, 105, 575-584.	3.3	18
20	Fiveâ€year clinical outcomes of sirolimusâ€eluting versus paclitaxelâ€eluting stents in highâ€risk patients. Catheterization and Cardiovascular Interventions, 2011, 77, 494-501.	1.7	17
21	Sex differences in the outcome after percutaneous coronary intervention – A propensity matching analysis. Cardiovascular Revascularization Medicine, 2019, 20, 101-107.	0.8	17
22	Comparative prognostic value of postprocedural creatine kinase myocardial band and highâ€sensitivity troponin T in patients with nonâ€STâ€segment elevation myocardial infarction undergoing percutaneous coronary intervention. Catheterization and Cardiovascular Interventions, 2018, 91, 215-223.	1.7	16
23	Comparative efficacy of two paclitaxel-coated balloons with different excipient coatings in patients with coronary in-stent restenosis. International Journal of Cardiology, 2018, 252, 57-62.	1.7	16
24	High-sensitivity cardiac troponin T and prognosis in patients with ST-segment elevation myocardial infarction. Journal of Cardiology, 2018, 72, 220-226.	1.9	15
25	Angiographic outcomes with biodegradable polymer and permanent polymer drugâ€eluting stents. Catheterization and Cardiovascular Interventions, 2011, 78, 161-166.	1.7	13
26	Secondâ€versus firstâ€generation "Limusâ€â€eluting stents in diabetic patients with coronary artery disease: A randomized comparison in setting of ISARâ€TESTâ€4 trial. Catheterization and Cardiovascular Interventions, 2013, 82, E769-76.	1.7	13
27	Five-year clinical outcomes in patients with diabetes mellitus treated with polymer-free sirolimus- and probucol-eluting stents versus second-generation zotarolimus-eluting stents: a subgroup analysis of a randomized controlled trial. Cardiovascular Diabetology, 2016, 15, 124.	6.8	13
28	Long-Term Prognostic Impact of Restenosis of the Unprotected Left Main Coronary Artery Requiring Repeat Revascularization. JACC: Cardiovascular Interventions, 2020, 13, 2266-2274.	2.9	13
29	Sirolimus-eluting versus paclitaxel-eluting stents in diabetic and non-diabetic patients within sirolimus-eluting stent restenosis: Results from the ISAR-DESIRE 2 trial. Cardiovascular Revascularization Medicine, 2014, 15, 69-75.	0.8	12
30	Ticagrelor or Prasugrel for Patients With Acute Coronary Syndrome Treated With Percutaneous Coronary Intervention. JAMA Cardiology, 2021, 6, 1121.	6.1	11
31	Impact of inhospital stent thrombosis and cerebrovascular accidents on long-term prognosis after percutaneous coronary intervention. American Heart Journal, 2014, 168, 862-868.e1.	2.7	9
32	Relation of Ratio of Left Ventricular Ejection Fraction to Left Ventricular End-Diastolic Pressure to Long-Term Prognosis After ST-Segment Elevation Acute Myocardial Infarction. American Journal of Cardiology, 2019, 123, 199-205.	1.6	9
33	Early Aspirin Discontinuation After Coronary Stenting: A Systematic Review and Metaâ€Analysis. Journal of the American Heart Association, 2021, 10, e018304.	3.7	9
34	Prognostic value of glomerular function estimated by Cockcroft-Gault creatinine clearance, MDRD-4, CKD-EPI and European Kidney Function Consortium equations in patients with acute coronary syndromes. Clinica Chimica Acta, 2021, 523, 106-113.	1.1	9
35	Prognostic value of gamma-glutamyl transferase in patients with diabetes mellitus and coronary artery disease. Clinical Biochemistry, 2016, 49, 1127-1132.	1.9	8
36	Relationship of left ventricular endâ€diastolic pressure with extent of myocardial ischemia, myocardial salvage and longâ€term outcome in patients with STâ€segment elevation myocardial infarction. Catheterization and Cardiovascular Interventions, 2019, 93, 901-909.	1.7	8

SEBASTIAN KUFNER

#	Article	IF	CITATIONS
37	Impact of perfusion restoration at epicardial and tissue levels on markers of myocardial necrosis and clinical outcome of patients with acute myocardial infarction. EuroIntervention, 2011, 7, 128-135.	3.2	8
38	Myocardial Perfusion Grade, Myocardial Salvage Indices and Long-Term Mortality in Patients With Acute Myocardial Infarction and Full Restoration of Epicardial Blood Flow After Primary Percutaneous Coronary Intervention. Revista Espanola De Cardiologia (English Ed), 2010, 63, 770-778.	0.6	7
39	Predicting factors for long-term survival in patients with out-of-hospital cardiac arrest – A propensity score-matched analysis. PLoS ONE, 2020, 15, e0218634.	2.5	7
40	Ten-year clinical outcomes of polymer-free versus durable polymer new-generation drug-eluting stent in patients with coronary artery disease with and without diabetes mellitus. Clinical Research in Cardiology, 2021, 110, 1586-1598.	3.3	7
41	Changes in high-sensitivity troponin after drug-coated balloon angioplasty for drug-eluting stent restenosis. EuroIntervention, 2017, 13, 962-969.	3.2	6
42	Target and non-target vessel related events at 10 years post percutaneous coronary intervention. Clinical Research in Cardiology, 2022, 111, 787-794.	3.3	6
43	Tenâ€Year Clinical Outcomes of Biodegradable Versus Durable Polymer Newâ€Generation Drugâ€Eluting Stent in Patients With Coronary Artery Disease With and Without Diabetes Mellitus. Journal of the American Heart Association, 2021, 10, e020165.	3.7	5
44	Longâ€ŧerm clinical outcomes after drug eluting stent implantation with and without stent overlap. Catheterization and Cardiovascular Interventions, 2022, 99, 541-551.	1.7	5
45	Ten-year patterns of stent thrombosis after percutaneous coronary intervention with new- versus early-generation drug-eluting stents: insights from the DECADE cooperation. Revista Espanola De Cardiologia (English Ed), 2022, , .	0.6	5
46	Stent Optimization Using Optical Coherence Tomography and Its Prognostic Implications After Percutaneous Coronary Intervention. Journal of the American Heart Association, 2022, 11, e023493.	3.7	5
47	What Treatment Should We Dare in Patients With In-Stent Restenosis?. JACC: Cardiovascular Interventions, 2018, 11, 284-286.	2.9	4
48	Efficacy of drugâ€coated balloon angioplasty in early versus late occurring drugâ€eluting stent restenosis: A pooled analysis from the randomized ISAR DESIRE 3 and DESIRE 4 trials. Catheterization and Cardiovascular Interventions, 2020, 96, 1008-1015.	1.7	4
49	U-shaped association of central pulse pressure with long-term prognosis after ST-segment elevation myocardial infarction. Heart and Vessels, 2019, 34, 1104-1112.	1.2	3
50	Procedural and clinical performance of dual―versus singleâ€catheter strategy for transradial coronary angiography: A metaâ€analysis of randomized trials. Catheterization and Cardiovascular Interventions, 2020, 96, 276-282.	1.7	2
51	A prospective trial of a novel <scp>lowâ€dose paclitaxelâ€coated</scp> balloon therapy in patients with restenosis in <scp>drugâ€eluting</scp> coronary stents Intracoronary Stenting and Angiographic Results: Optimizing Treatment of Drug Eluting Stent <scp>Inâ€stent</scp> REstenosis <scp>3A</scp> (ISARâ€DESIRE 3A). Catheterization and Cardiovascular Interventions, 2022, 99, 754-762.	1.7	2
52	Diagnosis and management of intramyocardial hematoma after coronary artery perforation. Coronary Artery Disease, 2016, 27, 327-330.	0.7	1
53	Diabetes mellitus and femoropopliteal in-stent restenosis. Vasa - European Journal of Vascular Medicine, 2022, , .	1.4	1
54	Drug-eluting stents for drug-eluting stent restenosis. Coronary Artery Disease, 2014, 25, 633-635.	0.7	0

#	Article	IF	CITATIONS
55	Ten-Year Clinical Outcomes in Patients With Acute Coronary Syndrome Treated With Biodegradable, Permanent-Polymer or Polymer-Free Drug-Eluting Stents Journal of Invasive Cardiology, 2022, 34, E266-E273.	0.4	0